WGS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GeneDx Holdings Corp. Securities Lawsuit - Contact Levi & Korsinsky
GeneDx Promised Fabric Genomics Would "Transform Static Data Into Recurring Revenue" and "Unlock Software-Based Revenue Streams" — Instead, Investors Got a $31.2 Million Write-Off and a 49% Stock Collapse
The promise: "Fabric Genomics' software transforms static data into a dynamic, recurring revenue-generating platform — driving growth through software margins and high-leverage interpretation services across geographies and clinical use cases."
The reality: a $31.2 million impairment charge, an admission that Fabric was suited only for international markets, and a $65 million reduction in full-year revenue guidance.
Levi & Korsinsky, LLP highlights the contrast between GeneDx Holdings Corp.'s (NASDAQ: WGS) promises to investors and the actual results of its Fabric Genomics acquisition. Shareholders who purchased WGS securities between April 16, 2025 and May 4, 2026 and suffered losses may be entitled to compensation. Find out if you can recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
